000283078 001__ 283078
000283078 005__ 20251229161137.0
000283078 0247_ $$2doi$$a10.1002/alz70860_097492
000283078 0247_ $$2pmid$$apmid:41435243
000283078 0247_ $$2pmc$$apmc:PMC12726345
000283078 0247_ $$2ISSN$$a1552-5260
000283078 0247_ $$2ISSN$$a1552-5279
000283078 037__ $$aDZNE-2025-01485
000283078 041__ $$aEnglish
000283078 082__ $$a610
000283078 1001_ $$0P:(DE-2719)9001870$$aBlotenberg, Iris$$b0$$eFirst author$$udzne
000283078 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283078 245__ $$aModifiable factors predict symptom progression in dementia over eight years
000283078 260__ $$c2025
000283078 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767020931_31203
000283078 3367_ $$033$$2EndNote$$aConference Paper
000283078 3367_ $$2BibTeX$$aINPROCEEDINGS
000283078 3367_ $$2DRIVER$$aconferenceObject
000283078 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283078 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283078 3367_ $$2ORCID$$aOTHER
000283078 520__ $$aThe aim of the present study was to investigate the association between modifiable factors and symptom progression in people with dementia over a period of up to eight years.We used data from a German cohort of community-dwelling individuals who screened positive for dementia in primary care. They underwent comprehensive annual in-home-assessments for up to eight years by specially trained nurses. The following modifiable factors were considered: low education, hearing impairment (and its treatment), hypertension (and its treatment), alcohol consumption, obesity, smoking, depression, social isolation, physical inactivity, diabetes (and its treatment) and visual impairment. We used multilevel growth curve models to investigate the role of modifiable risk factors on cognitive trajectories and trajectories in daily functioning.Higher education was associated with higher cognitive status at the beginning of the study, but also with faster cognitive decline over time. People receiving anti-diabetic medications showed slower cognitive decline, while depression and visual impairment were associated with lower levels of daily functioning at baseline and faster cognitive decline over the eight-year study period. We found no association of hearing impairment (or its treatment), hypertension (or its treatment), alcohol consumption, obesity, smoking, lack of social support and physical inactivity with the rate of symptom progression.Our study found evidence that several potentially modifiable risk factors influenced symptom progression in dementia over up to eight years. Cognitive reserve through education showed a positive effect, which reversed over time, and depressive symptoms were linked to less favorable progression. Treating comorbidities like diabetes and visual impairment may positively impact dementia symptoms. Modifiable risk factors are promising targets for tertiary prevention and should be explored further.
000283078 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283078 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283078 650_2 $$2MeSH$$aHumans
000283078 650_2 $$2MeSH$$aMale
000283078 650_2 $$2MeSH$$aFemale
000283078 650_2 $$2MeSH$$aAged
000283078 650_2 $$2MeSH$$aDementia: epidemiology
000283078 650_2 $$2MeSH$$aRisk Factors
000283078 650_2 $$2MeSH$$aGermany: epidemiology
000283078 650_2 $$2MeSH$$aDisease Progression
000283078 650_2 $$2MeSH$$aPublic Health
000283078 650_2 $$2MeSH$$aAged, 80 and over
000283078 650_2 $$2MeSH$$aCognitive Dysfunction: epidemiology
000283078 650_2 $$2MeSH$$aCohort Studies
000283078 7001_ $$aWittström, Felix$$b1
000283078 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b2$$udzne
000283078 7001_ $$0P:(DE-2719)9001238$$aPlaten, Moritz$$b3$$udzne
000283078 7001_ $$0P:(DE-2719)2810631$$aWucherer, Diana$$b4$$udzne
000283078 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b5$$udzne
000283078 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b6$$udzne
000283078 7001_ $$0P:(DE-2719)2290613$$aThyrian, Jochen René$$b7$$eLast author$$udzne
000283078 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70860_097492$$gVol. 21 Suppl 6, no. Suppl 6, p. e097492$$nSuppl 6$$pe097492$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283078 8564_ $$uhttps://pub.dzne.de/record/283078/files/DZNE-2025-1485.pdf$$yRestricted
000283078 8564_ $$uhttps://pub.dzne.de/record/283078/files/DZNE-2025-1485.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283078 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001870$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283078 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283078 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001238$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283078 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283078 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283078 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283078 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2290613$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283078 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283078 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283078 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283078 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283078 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283078 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283078 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283078 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283078 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283078 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283078 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283078 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x0
000283078 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x1
000283078 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x2
000283078 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x3
000283078 980__ $$aabstract
000283078 980__ $$aEDITORS
000283078 980__ $$aVDBINPRINT
000283078 980__ $$ajournal
000283078 980__ $$aI:(DE-2719)1510800
000283078 980__ $$aI:(DE-2719)5000067
000283078 980__ $$aI:(DE-2719)1510100
000283078 980__ $$aI:(DE-2719)1510600
000283078 980__ $$aUNRESTRICTED